Abstract
The current way to increase efficacy of cancer therapy is the use of molecular recognition of aberrantly expressed gene products for selective treatment. However, only a fraction of the patients have tumors with a particular molecular target. Radionuclide imaging of molecular targets might help to stratify patient for cancer treatment. Affibody molecules are scaffold proteins, which can be selected for high affinity recognition of proteinaceous molecular targets. The capacity to re-fold under physiological conditions allows labeling of Affibody molecules in a broad range of pH and temperatures with preserved binding properties. Peptide synthesis or introduction of a unique cysteine enables sitespecific labeling of Affibody molecules, resulting in uniform conjugates with well-defined pharmacological characteristics. The small size (7 kDa) of Affibody molecules provides rapid extravasation, rapid tumor penetration, and rapid clearance of unbound tracer from healthy organs and tissues. In combination with sub-nanomolar affinity, this results in high contrast in vivo imaging a few hours after injection. Excellent targeting has been demonstrated in pre-clinical studies with HER2-targeting Affibody molecules labeled with 99mTc and 111In for single photon computed tomography (SPECT), and 18F, 64Cu, 124I and 68Ga for positron emission tomography (PET). Pilot clinical data confirm the high potential of Affibody molecules.
Keywords: Affibody molecules, EGFR, HER2, molecular imaging, radionuclide, scaffold proteins, targeting
Current Pharmaceutical Biotechnology
Title: Radionuclide Molecular Imaging Using Affibody Molecules
Volume: 11 Issue: 6
Author(s): Sara Ahlgren and Vladimir Tolmachev
Affiliation:
Keywords: Affibody molecules, EGFR, HER2, molecular imaging, radionuclide, scaffold proteins, targeting
Abstract: The current way to increase efficacy of cancer therapy is the use of molecular recognition of aberrantly expressed gene products for selective treatment. However, only a fraction of the patients have tumors with a particular molecular target. Radionuclide imaging of molecular targets might help to stratify patient for cancer treatment. Affibody molecules are scaffold proteins, which can be selected for high affinity recognition of proteinaceous molecular targets. The capacity to re-fold under physiological conditions allows labeling of Affibody molecules in a broad range of pH and temperatures with preserved binding properties. Peptide synthesis or introduction of a unique cysteine enables sitespecific labeling of Affibody molecules, resulting in uniform conjugates with well-defined pharmacological characteristics. The small size (7 kDa) of Affibody molecules provides rapid extravasation, rapid tumor penetration, and rapid clearance of unbound tracer from healthy organs and tissues. In combination with sub-nanomolar affinity, this results in high contrast in vivo imaging a few hours after injection. Excellent targeting has been demonstrated in pre-clinical studies with HER2-targeting Affibody molecules labeled with 99mTc and 111In for single photon computed tomography (SPECT), and 18F, 64Cu, 124I and 68Ga for positron emission tomography (PET). Pilot clinical data confirm the high potential of Affibody molecules.
Export Options
About this article
Cite this article as:
Ahlgren Sara and Tolmachev Vladimir, Radionuclide Molecular Imaging Using Affibody Molecules, Current Pharmaceutical Biotechnology 2010; 11 (6) . https://dx.doi.org/10.2174/138920110792246609
DOI https://dx.doi.org/10.2174/138920110792246609 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current and Next Generation Topical Anti-Skin Cancer Therapeutics
Drug Delivery Letters Monitoring the Inflammatory Process by Surface Enhanced Nanoimaging Microscopy
Current Neurovascular Research Research Progress of Exogenous Plant MiRNAs in Cross-Kingdom Regulation
Current Bioinformatics Editorial [Hot Topic: Tyrosine Kinase Inhibitors in Cancer Therapy (Guest Editor: S. Eckhardt)]
Anti-Cancer Agents in Medicinal Chemistry Tissue Elastography: Advances in Imaging the Mechanical Properties of Tissue
Recent Patents on Electrical Engineering Classification of Human Pregnane X Receptor (hPXR) Activators and Non-Activators by Machine Learning Techniques: A Multifaceted Approach
Combinatorial Chemistry & High Throughput Screening Potential for Predicting Toxicity and Response of Fluoropyrimidines in Patients
Current Drug Targets Aptamers: Molecular Tools for Medical Diagnosis
Current Topics in Medicinal Chemistry Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design How Do Periodontal Infections Affect the Onset and Progression of Alzheimer’s Disease?
CNS & Neurological Disorders - Drug Targets Investigation of New Phenothiazine and Carbazole Derivatives as Potential Inhibitors of Human Farnesyltransferase
Letters in Drug Design & Discovery Thiazolidinedione: A Privileged Scaffold for the Development of Anticancer Agents
Current Topics in Medicinal Chemistry Quantum Dots in the Therapy: Current Trends and Perspectives
Mini-Reviews in Medicinal Chemistry Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer
Mini-Reviews in Medicinal Chemistry Exosome as a Natural Gene Delivery Vector for Cancer Treatment
Current Cancer Drug Targets Construction of Macromolecular Assemblages in Eukaryotic Processes and their Role in Human Disease: Linking RINGs Together
Current Protein & Peptide Science Synergistic Effect of α-Solanine and Cisplatin Induces Apoptosis and Enhances Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Progranulin Regulates Inflammation and Tumor
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Role of Diet and Nutrition on the Alteration of the Quality and Quantity of Stem Cells in Human Aging and the Diseases of Aging
Current Pharmaceutical Design A Review of the ADAMTS Family, Pharmaceutical Targets of the Future
Current Pharmaceutical Design